A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of PF-08052667 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)

The primary objective of this study is to evaluate the efficacy of PF-08052667 in patients diagnosed with non-muscle invasive bladder cancer. Assessment of this therapeutic agent is intended to determine its clinical impact on disease progression or response within this specific patient population. 5

This clinical trial involves a total of 200 patients. The study population consists of both male and female individuals. Participants are characterized by a diagnosis of non-muscle invasive bladder cancer. The age range for the cohort is categorized within the 3 to 4 age group codes.

This Phase 1 clinical trial utilizes a research methodology to evaluate the study medicine PF-08052667 in individuals diagnosed with non-muscle invasive bladder cancer. The study design involves a sequence of clinical assessments beginning with a screening visit to determine eligibility. Following enrollment, participants undergo scheduled follow-up visits to monitor clinical progress and safety. The process concludes with an end-of-study visit. The total duration of participant involvement is determined by the specific protocol requirements. Early termination from the study may occur based on predefined clinical conditions or safety criteria.

The assessment of efficacy in this study concerning non-muscle invasive bladder cancer is not specified.